VarmX

Leiden

About VarmX

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center (LUMC), founded in 2016 by professor Pieter Reitsma. He is a world leading expert in hemostasis and thrombosis. The company’s leading product in development, PseudoXa, is a new therapeutic protein to stop acute bleeding in patients taking factor Xa inhibitors, such as the commonly used apixaban.
YEAR FOUNDED:
2016
LEADERSHIP:
Founder: Pieter Reitsma

10 articles about VarmX

VarmX to Attend LSX World Congress and Bio€quity Europe in Q2 2024

3/28/2024

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, announces that it will be attending the LSX World Congress and presenting at Bio€quity Europe.
VarmX Promotes CSO Dr. Jeffrey Lawson to New CEO and Moves to New State-of-the-Art Facility

10/12/2023

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, announces that Dr. Jeffrey Lawson, currently the Company’s Chief Scientific Officer, will assume the role of CEO, succeeding Dr. Jan Öhrström who will continue as Chairman.
VarmX Appoints Dr. Jeffrey Lawson, MD, PhD as Chief Scientific Officer

3/8/2023

VarmX today announces the appointment of Dr. Jeffrey Lawson as its new Chief Scientific Officer (CSO).
First Subjects Dosed in First-in-Human Trial for VarmX’s Anticoagulant Reversal Agent, VMX-C001

12/15/2021

VarmX announced treatment of the first subjects in its first-in-human study for lead compound VMX-C001, and the transition of VarmX from a preclinical into a clinical company.
VarmX Awarded Funding From the EIC Accelerator to Support Scale up and Manufacturing of VMX-C001

10/21/2021

VarmX has been awarded up to €17.5 million from the European Innovation Council Accelerator, subject to negotiation, to upscale and accelerate cost effective manufacturing of its lead compound, VMX-C001.
VarmX appoints Dr. Gerard Short as Chief Medical Officer

1/27/2021

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, announces the appointment of Dr. Gerard Short, MBBS, as Chief Medical Officer.
VarmX Raises €32 Million in Series B Financing to Develop Innovative Reversal Agent for the Treatment and Prevention of Severe Bleeding in Patients on Oral Anticoagulants

7/8/2020

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, announces the completion of a €32 million Series B financing round.
VarmX Raises € 12.5 Million to Develop Modified Blood Coagulation Factor X for Treating Severe Bleeding in Patients Using Anti-Coagulants

7/2/2018

VarmX, today announced the closing of a Series A financing round of € 7.5 million.
VarmX Announces Publication In Nature Communications Of Groundbreaking Snake Venom Inspired Approach To Restore Blood Clotting In Patients Using Anticoagulants

9/19/2017
VarmX Raises Seed Capital For Development Of Modified Blood Coagulation Factor X

6/27/2017